Full Press Release Details
Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024
conference call and webcast at 4:30 pm ET on that day
Boca Raton, Florida, July 25, 2024 (GLOBE
NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology company focused
on developing treatments that harness a patient's innate immune system to fight disease, today announced that it will host
a conference call on Thursday, August 1, 2024, at 4:30 PM EDT to discuss results for its first quarter ended June 30, 2024 and to provide
Conference Call Information
To participate in this event, dial approximately
5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio Fourth Quarter Conference Call when reaching the operator.
Date: August 1, 2024
Time: 4:30 PM Eastern Time
Participant Dial-in: 1-800-225-9448 Participant Dial-in (international): 1-203-518-9708
Conference ID: INMUNE
A live audio webcast of the call can be accessed
by clicking here or using this link:
A transcript will follow approximately 24
hours from the scheduled call. A replay will also be available through August 8, 2024 by dialing 1-844-512-2921 or 1-412-317-6671 (international)
and entering PIN no. 11156467.
About INmune Bio Inc.
INmune Bio, Inc. is a publicly
traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight
disease. INmune Bio has two product platforms that are both in clinical trials: The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product
platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a
mechanistic driver of many diseases. XPRO, the first of several DN-TNF products, is in clinical trials to determine if it can treat patients
with Mild Alzheimer's disease. Additional therapeutic indications including d treatment-resistant depression and oncology will be
pursued when resources allow. The Natural Killer Cell Priming Platform includes INKmune , a therapy developed to prime a patient's
NK cells to treat patients with cancer. INKmune uses a precision medicine approach for the treatment of a wide variety of hematologic
and solid tumor malignancies. The INKmune trial is enrolling patients into a US Phase I/II trial in men with metastatic castrate resistant
prostate cancer. To learn more, please visit www.inmunebio.com.
Forward Looking Statements
Clinical trials are in early stages and there
is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical
facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that
term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on
current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances
may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03 ,
XPro1595, and INKmune are still in clinical trials or preparing to start clinical trials and have not been approved by the US Food
and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory
body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current
expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to produce more drug for
clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research
and development, clinical studies and future product commercialization; and, the Company's business, research, product development,
regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail
in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K,
the Company's Quarterly Reports on Form 10-Q and the Company's Current Reports on Form 8-K. The Company assumes no obligation
to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
David Moss, CFO (858) 964-3720
Managing Director - LifeSci Advisors